A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor

JAMA Dermatology

Volumn 152, Issue 1, 2016, Pages 106-108

  Chang, Anne Lynn S ^a   Kim, Jinah ^a   Luciano, Richard ^a   Sullivan Chang, Loretta ^a   Colevas, Alexander D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CYTOKERATIN 5; CYTOKERATIN 6; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN P63; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTHRALGIA; CANCER IMMUNOTHERAPY; CANCER SURGERY; CASE REPORT; CHILL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; KERATINIZATION; KERATINOCYTE; LETTER; MALAISE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROTIDECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SKIN CARCINOMA; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; PATHOLOGY; SKIN NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HUMANS; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84955325707     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.2705     Document Type: Letter

References (6)

1. Jarkowski A III, Hare R, Loud P, et al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a review of the literature [published online May 29, 2014]. Am J Clin Oncol. 2014.
2. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
3. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957-966.
4. Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 2015;51(3):221-228.
5. Fury M, Ou SI, Balmanoukian A, et al. Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody in patients with head and neck cancer. Ann Oncol. 2014;25(suppl 4):iv340-iv356.
6. Malaspina TS, Gasparoto TH, Costa MR, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother. 2011;60(7):965-974.